This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100. Visits were scheduled at weeks 1, 2, 4 and 12, and every 3 months thereafter. After 26 weeks, glycated haemoglobin (HbA1c) reductions were greater with IDegLira versus IGlar U100 (-21.5 vs. -16.4 mmol/mol [-2.0 vs. -1.5%]), as was the percentage of participants achieving HbA1c <53 mmol/mol (78.7% vs. 55.7%) and HbA1c targets without weight gain and/or hypoglycaemia. Estimated treatment differences for insulin dose (-13.01 U) and body weight change (-1.57 kg) significantly favoured IDegLira. The hypoglycaemia rate was 44% lower with IDegLira versus IGlar U100. Safety results were similar. In a trial resembling clinical practice, more participants receiving IDegLira than IGlar U100 met treatment targets, supporting use of IDegLira as an initial injectable therapy for people with T2D uncontrolled on OADs and eligible for insulin initiation.

Area of Endocrinology Metabolism and Nutrition Faculty of Medical Sciences National University of Cuyo Mendoza Argentina

Brigham and Women's Hospital Boston Massachusetts United States

Department of Clinical and Molecular Medicine Sapienza University of Rome Rome Italy

Department of Endocrinology and Metabolism Hacettepe University School of Medicine Ankara Turkey

Institute for Clinical and Experimental Medicine and Institute of Endocrinology Prague Czech Republic

MedStar Health Research Institute Hyattsville Maryland United States

Novo Nordisk A S Søborg Denmark

Zobrazit více v PubMed

American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes‐2019. Diabetes Care. 2019;42:S90‐S102. PubMed

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669‐2701. PubMed PMC

Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Griffin MR. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study. BMC Endocr Disord. 2016;16:32. PubMed PMC

Blonde L, Raccah D, Lew E, et al. Treatment intensification in type 2 diabetes: A real‐world study of 2‐OAD regimens, GLP‐1 RAs, or basal insulin. Diabetes Ther. 2018;9:1169‐1184. PubMed PMC

Buysman EK, Fan T, Blauer‐Peterson C, Miller‐Wilson LA. Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin. Endocrinol Diabetes Metab. 2018;1:e00019. PubMed PMC

Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open‐label, randomised, 26‐week, treat‐to‐target trial in insulin‐naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885‐893. PubMed

Philis‐Tsimikas A, Billings LK, Busch R, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21:1399‐1408. PubMed PMC

Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naive people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34:189‐196. PubMed PMC

Gough SC, Bode BW, Woo VC, et al. One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial. Diabetes Obes Metab. 2015;17:965‐973. PubMed PMC

Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017;19:858‐865. PubMed PMC

Aroda VR, Gonzalez‐Galvez G, Gron R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open‐label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:596‐605. PubMed

International Conference of Harmonisation . ICH Harmonised Tripartite Guideline Good Clinical Practice; 1996.

World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191‐2194. PubMed

Marso SP, Daniels GH, Brown‐Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311‐322. PubMed PMC

Abdul‐Ghani M, DeFronzo RA. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP‐1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care. 2017;40:1121‐1127. PubMed PMC

Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175‐184. PubMed PMC

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859‐864. PubMed

Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723‐732. PubMed PMC